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Molecular knockdown of disease proteins and restoration of wild-
type activity represent a promising but challenging strategy for
the treatment of diseases that result from the accumulation of
misfolded proteins (i.e., Huntington disease, amyotrophic lateral
sclerosis, and α-1 antitrypsin deficiency). In this study we used
alpha-1 antitrypsin (AAT) deficiency with the piZZ mutant pheno-
type as a model system to evaluate the efficiency of gene-delivery
approaches that both silence the piZZ transcript (e.g., shRNA) and
restore circulating wild-type AAT expression from resistant codon-
optimized AAT (AAT-opt) transgene cassette using adeno-associ-
ated virus (AAV) vector delivery. After systemic injection of a self-
complimentary AAV serotype 8 (scAAV8) vector encoding shRNA
in piZZ transgenic mice, both mutant AAT mRNA in the liver and
defected serum protein level were inhibited by 95%, whereas liver
pathology, as monitored by dPAS and fibrosis staining, reversed.
To restore blood AAT levels in AAV8/shRNA-treated mice, several
strategies to restore functional AAT levels were tested, including
using AAV AAT-opt transgene cassettes targeted to muscle and
liver, or combination vectors carrying piZZ shRNA and AAT-opt
transgenes separately, or a single bicistronic AAV vector. With
these molecular approaches, we observed over 90% knockdown
of mutant AAT with a 13- to 30-fold increase of circulating wild-
type AAT protein from the shRNA-resistant AAT-opt cassette. The
molecular approaches applied in this study can simultaneously
prevent liver pathology and restore blood AAT concentration in
AAT deficiencies. Based on these observations, similar gene-ther-
apy strategies could be considered for any diseases caused by
accumulation of misfolded proteins.
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Anumber of diseases are caused by misfolded proteins (e.g.,cycstic fibrosis). In addition, it is well known that misfolded
proteins accumulate intracellularly and cause cell damage,
leading to diseases. For example, superoxide dismutase 1 mu-
tations result in protein aggregation that leads to amyotrophic
lateral sclerosis, Alzheimer’s disease, and Huntington disease are
related to mutant amyloid-β (Aβ) and huntingtin (Htt) protein
accumulations, respectively (1). Clearance of these mutant pro-
teins by drugs has resulted in improvement of the clinical out-
come. To rescue the complete phenotype, restoration of normal
protein gene therapy is currently being evaluated. In this study,
we used α-1 antitrypsin (AAT) deficiency with the piZZ phe-
notype (glu 342 → lys: GAG-AAG) as a disease model to eval-
uate the efficiency of silencing the piZZ transcript and restoring
circulating AAT levels using adeno-associated virus (AAV)
vector-mediated gene delivery.
AAT deficiency with the piZZ mutation results in severe liver
disease and lung damage caused by misfolded protein accumu-
lation in the endoplasmic reticulum of the liver cells and low levels
of AAT in circulation, respectively. Currently, liver trans-
plantation is the only treatment able to cure the disease. Gene
therapy is an attractive alternative for AAT deficiency because of
the well-defined therapeutic endpoint and its wide therapeutic
index. Several vectors have been shown to express detectable se-
rum levels of hAAT in animal models. AAV vectors have the
advantage of high in vivo transgene expression, low toxicity, and
the capacity to express its transgene in both mitotically active and
quiescent cells. These characteristics of AAV are especially suited
for the transfer and persistent expression of the human AAT gene
(2). Clinical trials with AAV/hAAT have been performed (3, 4).
AAV2 transduction in the liver can initiate very high transgene
expression with a fivefold increase in AAT expression relative to
that frommuscle (5). Current mechanisms for rAAV transduction
involve the conversion of a single-stranded (ss) to a double-
stranded (ds) genome. To eliminate the necessary ss- to ds-ge-
nome conversion, we have recently developed a unique form of
AAV vector that packages a ds template (dsAAV), also called
a self-complementary (sc) genome (6). These vectors are not
subject to the classic “slow onset” of gene expression typically
observed with traditional ssAAV vectors. Recently, 12 serotypes
of AAV have been isolated and used as gene-delivery vehicles,
with over 100 additional variants described. The capsid sequences
of AAV serotypes vary in their homology to type 2. Heterogeneity
is found predominantly within the exposed regions on the capsid
surface of different serotypes, suggesting serotypes may have
distinct mechanisms of transduction. To date, different serotypes
of AAV vectors and transgene cassettes have been used to im-
prove liver transduction; serotypes 1, 6, 8, and 9 showed improved
transduction over AAV2, with AAV8 being the best (7).
Lung disease associated with AAT deficiency can be prevented
by replenishment of the deficient gene product via gene therapy.
However, this strategy does not prevent the liver disease caused by
intracellular accumulation of the misfolded proteins. Strategies to
prevent liver disease should focus on correction of the mutant
gene at the DNA or mRNA level, or suppression of mutant RNA
expression. A few practical methods have been tested to repair or
shut down the expression of mutant genes, including antisense
oligomers, chimeric RNA:DNA oligomers, and ribozymes. Post-
transcriptional silencing by siRNA has emerged as a powerful tool
for genetic analyses in mammalian cells and has the potential to
produce novel therapeutics. Unfortunately, oligonucleotide-me-
diated siRNA transfer suffers from several limitations, such as
high cost, nonspecific toxicity of transfection, and transient sup-
pression of gene expression. To overcome these problems, several
groups have described alternative systems for siRNA expression
within mammalian cells that rely on DNA vectors. In general,
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theseDNA vectors use an RNApolymerase III (Pol III) promoter
to express short dsRNA in the form of an inverted repeat se-
quence containing a hairpin loop. Such small hairpin RNAs
(shRNA) are efficiently processed into siRNAs inside the cells
and achieved sequence-specific gene silencing. AAV vectors have
been used to deliver shRNA for a variety of purposes. Here we
used an AAV vector to package an AAT-targeting shRNA to
knock down piZZ transcripts in the liver. Decreased amounts of
piZZ protein in the liver cells may delay liver disease development
or progression. Alone, piZZ knockdown cannot resolve other
complications caused by AAT deficiency, but supplementation of
shRNA-resistant wild-type AAT may solve the problem.
In the present study, we have shown that AAV vectors encoding
a single AAT shRNA are effective in decreasing human AAT
expression in cell lines and in transgenic mice with the piZZ
phenotype. Muscular administration of an AAV6/AAT vector
restored AAT expression in the blood. Utilization of an optimized
AAT construct (AAT-opt) delivered by an AAV vector not only
induced higher transgene expression than wild-type AAT cDNA,
but also escaped the degradation of wild-type AAT-targeted
shRNA when AAT-opt and shRNA were simultaneously de-
livered into the liver via either a single vector or dual vectors.
Results
Silencing Effect of shRNA on AAT. siRNA has been widely used to
knock down target gene expression for a variety of purposes. We
have designed three siRNAs that have the potential to silence
AAT expression (Table S1). To test the siRNA silencing effect,
we have established the cell lines 293/wild-type AAT and 293/
piZZ. After transfection of three candidate piZZ/siRNA oligos
into these cells, AAT in the supernatant was measured at 48 h.
All three piZZ/siRNA oligos exerted AAT gene silencing, with
over 70% efficiency in both 293/wild-type AAT and 293/piZZ
cells (Fig. S1A). These three siRNAs were individually cloned
into scAAV constructs, which were encapsidated into the AAV
serotype-2 virion. After transduction of 293/wild-type AAT or
293/piZZ with AAV2/shRNA vectors, the shRNA2 construct
exerted a better silencing effect than the other two shRNAs (Fig.
S1B); thus, shRNA2 was used for all in vivo studies.
To examine whether the AAV/shRNA2 vector promoted AAT
gene silencing in the mouse liver, we packaged an AAT shRNA2
construct into the AAV8 capsid, because AAV8 has been shown
to transduce the mouse liver with almost 100% efficiency with
6 × 1010 particles of double-stranded GFP virus (Fig. S2). We
coadministered 6 × 1010 particles of AAV8/shRNA2 and 1 × 1011
particles of AAV2/CBA-AAT viruses into wild-type BALB/c
mice via tail-vein injection. As shown in Fig. S3A, the co-
administration of AAV8/shRNA significantly inhibited AAT
expression in blood compared with coadministration of AAV8/
scramble shRNA or control with only AAV2/CBA-AAT in-
jection (P < 0.05). There was no significant difference in AAT
expression between the latter two groups (P > 0.05). We also
detected liver function after AAV8/shRNA administration to
assess possible liver toxicity from the shRNA, and no significant
change was observed between the shRNA group and controls
(Fig. S3 B and C).
Knockdown of piZZ-AAT Transgene Expression with shRNA. Next we
tested whether this shRNA construct could similarly inhibit
piZZ-AAT expression in piZZ-transgenic mice. At week 2 after
tail-vein injection of AAV8/shRNA2, compared with scramble
shRNA-treated mice and control without any treatment, the
AAT-shRNA construct led to over 95% suppression of AAT
expression (P < 0.05) (Fig. 1 A and B). We also measured the
AAT transcript in the liver with shRNA2 therapy, and consistent
with the AAT levels in the blood, AAT mRNA copy numbers in
the liver were over 100-fold lower than control and scramble
shRNA mice (Fig. 1C). To examine whether shRNA treatment
could improve liver pathology, which is associated with misfolded
mutant piZZ AAT protein accumulation and fibrosis in the liver,
we performed dPAS and Sirius Red staining of liver sections to
detect mutant piZZ-AAT inclusion in liver cells and fibrosis in
the liver, respectively. The liver sections were visualized by mi-
croscopy and processed by ImageJ software (Fig. S4). As shown
in Fig. 1, the accumulation of mutant piZZ-AAT protein was
significantly reduced in AAV8/shRNA2-treated mice compared
with mice with scramble shRNA (Fig. 1 D and E). Similarly, liver
fibrosis was reversed in mice with shRNA2 therapy (Fig. 1 D and
F). It is interesting to note that liver transaminase levels were
either not affected or slightly increased to levels similar to those
seen in nontreated control mice and with AAV8/scramble after
AAV application. However, AAV8/shRNA2-treated piZZ mice
showed a decline of both alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) liver enzymes (Fig. 1 G and
H). The silencing effect of shRNA on piZZ AAT expression was
still observed after 9 wk (Fig. S5). The data imply that admin-
istration of AAV8/shRNA2 can improve liver function because
of a shRNA-mediated decrease in piZZ protein accumulation.
Muscular Administration of AAV6/AAT Restored AAT Expression from
shRNA Silencing. The AAT deficiency caused by the piZZ muta-
tion results not only in liver disorders because of misfolded
protein accumulation, but also lung diseases resulting from the
lack of a functional gene product. shRNA knockdown can pre-
vent liver disease development but has no effect on the lung
disorders, as there is no replenishment of AAT deficiency in
circulation. One solution to this problem would be to use two
vectors: one for knockdown and the other for gene replacement.
An important obstacle to avoid in combining knockdown and
restoration is to specifically knock down the mutant transcript
but avoid knockdown of the corrected transcript. To circumvent
this problem, we initially targeted two different organs: liver for
piZZ knockdown and muscle for wild-type AAT replacement.
We chose to use AAV6 for intramuscular injection, as this AAV
serotype is considered one of the best for initiating transgene
expression in muscles (8). After injection of AAV8/shRNA2
vector systemically in piZZ mice, AAV6/AAT was injected into
muscle. At week 2 after AAV6 administration, blood AAT levels
were 10-fold higher in mice given the AAV6/AAT vector than in
mice given only the AAV8/shRNA knockdown vector (Fig. 2).
This result indicates that utilization of shRNA delivered by AAV
can efficiently knock down piZZ expression and AAT expression
can be restored from muscle transduced with an AAV vector
encoding a wild-type AAT construct.
Optimized AAT Transcript Is Resistant to Wild-Type AAT shRNA. As
explained above, same-cell gene knockdown and replacement can
result in therapeutic gene degradation if the shRNA sequence
matches the therapeutic transgene. One resolution for this ob-
stacle is the targeting of distinct tissues for knockdown and gene
replacement. However, in animal experiments, higher trans-
duction using AAV vectors can be achieved by targeting liver than
muscles; as such, knockdown and replacement events should
ideally occur in the liver. To achieve such a goal, the replacement
gene sequence would need to be altered in such a way as to render
it unique from the shRNA-recognition sequence. Optimization of
gene transcripts alter transgene sequences yet retain the trans-
lated amino acid sequence, and potentially increase the amount of
gene product. In our prior study, utilization of an optimized co-
agulation factor 9 (F9) induced fivefold higher transgene ex-
pression than a wild-type F9 construct with AAV delivery (9).
Based on this experience, we have generated an optimized AAT
cDNA construct (pTR/CBA-AAT-opt) for expression specifically
in mouse tissues. To test the ability of the AAT-opt construct to
mediate enhanced transgene expression, pTR/CBA-AAT or
pTR/CBA-AAT-opt was transfected into B16-F1 cells (mouse











melanoma cell line), and 24 h posttransfection the AAT levels
were detected by ELISA in the culture supernatant. The opti-
mized coding sequence resulted in a 30% increase in AAT se-
cretion compared with wild-type AAT DNA (Fig. S6A).
Interestingly, no difference in AAT expression (between AAT-
opt and AAT) was observed in a human cell line (293 HEKs),
perhaps because of the mouse-specific optimization algorithm
applied. The optimized AAT construct was packaged into an
AAV2 virion and injected into mice via the tail vein. Consistent
with the in vitro result, AAV2/AAT-opt produced 30% to 50%
more AAT in the blood than with the AAV2/AAT vector (Fig.
S6B). These results further support that optimization of theAAV-
packaged transgene can enhance trangene expression.
By alignment, there are key nucleotide mismatches between
wild-type and optimized AAT sequences at the siRNA targeting
location; specifically, four nucleotide mismatches were found for
siRNA2 between optimized and wild-type AAT constructs. To
test whether the expression of AAT from the optimized AAT
cDNA cannot be inhibited by our used siRNAs, we transfected
pCBA-AAT-opt or pCBA-AAT with each of three siRNAs (5
nM). The next day, we measured the AAT levels in the media.
As shown in Fig. S7A, all three siRNAs knocked down wild-type
AAT expression about 30% to 40%; however, there was no
suppression of AAT-opt expression (Fig. S7A). To confirm the
in vitro data in mice, coadministration of AAV8/shRNA2 and
AAV2/CBA-AAT-opt into mice via tail-vein injection demon-
strated no inhibition of AAT expression in the blood compared
with or without scramble shRNA (P > 0.05) (Fig. S7B). These
results suggest that AAT-opt can be used to escape mRNA
degradation by wild-type AAT siRNAs and potentially restore
AAT expression. Of note, no liver damage was observed with
coadministration of AAV8/shRNA and AAV2/CBA-AAT-opt
vectors (Fig. S7 C and D).
Coadministration of shRNA and Optimized AAT Delivered by Different
Serotypes of AAV Rescued AAT Expression. We and others have
previously shown that different AAV serotypes result in differ-
ential transduction dynamics and transgene expression in the
liver. Specifically, AAV8 and -9 induce a better and faster gene
expression than other serotypes. As AAV8 was chosen to deliver
shRNA, we wondered whether utilization of AAV9 to deliver the
AAT-opt construct into the liver could restore AAT expression
in the blood, as the piZZ transcript was silenced by AAV8/
shRNA. There is low cross-reactivity of neutralizing antibodies
between AAV9 and -8 capsids, suggesting that AAV9 may
transduce target cells using different receptors or coreceptors
from AAV8 (7). To avoid the potential competition of AAV9
and -8 during coinjection, we administered the AAV9/AAT-opt
vector into piZZ mice 24 h after administration of AAV8/
shRNA. After injection of AAV9/AAT-opt vector, AAT level in
Fig. 1. The knock down efficiency of shRNA in piZZ mice. Female piZZ mice at the age of 6 to 8 wk were injected with 6 × 1010 particles of dsAAV8/shRNA2 via
tail vein. At week 2 after AAV administration, blood and the liver were collected for evaluation of AAT expression and liver function. (A) AAT protein
concentration in the blood. *P < 0.05 compared with pre-shRNA treatment. (B) Inhibition of shRNA on AAT protein production was calculated by (1 − the
ratio of the AAT concentration in blood at week 2/the AAT level at preinjection) × 100%. *P < 0.05 compared with pre-shRNA treatment. (C) The expression
of piZZ transcripts with shRNA treatment. The AAT mRNA copy number was calculated with normalization to β-actin. The results are the mean of four mice,
and error bars indicate SD. *P < 0.05 compared with untreated or scramble shRNA-treated mice. (D) dPAS and Sirius Red staining of liver sections (original
magnification: × 10). (E and F) The quantification of dPAS staining and Sirius Red staining, respectivly. *P < 0.05 compared with scramble shRNA treatment. (G
and H) The measurement of liver transaminases ALT and AST, respectively. *P < 0.05 compared with pre-shRNA treatment.
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the blood was measured 2-wk postinjection. In the shRNA-only
group, compared with preinjection of AAV vector, over 95% in-
hibition of AAT expression was observed (Fig. 3A). However, the
AAT level in the blood was similar between pre- and posttreat-
ment in the group with shRNA plus AAV9/AAT-opt (P > 0.05)
(Fig. 3A). Similar results were also seen at week 4 after AAV9/
AAT-opt administration (Fig. S8A).We further collected the liver
and measured the level of AAT mRNA at week 2 postinjection.
With normalization to β-actin, about 100-fold lower wild-type
AAT mRNA copy number was observed in shRNA-treated mice
regardless of whether mice were treated with the AAV9/AAT-opt
vector or left untreated (P < 0.05) (Fig. 3B). No mRNA of AAT-
opt was detected in the untreated control and the shRNA-only
treated mice, whereas 20 copies of AAT-opt mRNA were
detected in mice with coadministration of shRNA and AAT-opt
(Fig. 3C). These results further support that the optimized AAT
construct can be used to escape shRNA-mediated degradation.
Restoration of AAT Expression and Silencing of piZZ in the Liver from
a Single AAV Vector.Although different serotypes of AAV vectors
may have very low neutralizing antibody cross-reactivity, and
here we have successfully demonstrated the use of a dual-vector
system to deliver shRNA and AAT-opt constructs separately into
the liver, there remain a number of uncertainties regarding AAV
biology, including serotype effects on AAV trafficking and en-
docytosis, which can impact the transduction efficiency of the
later-administered AAV vector. Therefore, it could be that in
some circumstances a single, dual-functioning vector would be
ideal. To achieve this result, we cloned the shRNA and AAT-opt
expression constructs into a single AAV cassette and studied the
effect of an AAV8 vector delivering a single construct encoding
shRNA2 and AAT-opt into the piZZ mouse liver, specifically on
piZZ-AAT transcript silencing in the liver and restoration of
normal circulating levels of AAT in the blood. Two weeks after
tail-vein injection of AAV8/shRNA-AAT-opt, no decrease in
blood AAT level was observed compared with that before in-
jection (Fig. 4A). Moreover, no changes in blood AAT concen-
trations were observed 8 wk after injection of AAV8/shRNA-
AAT-opt vector (Fig. S8B). As the ELISA is not specific for the
mutant or wild-type AAT protein, this result could be inter-
preted as either successful knockdown combined with successful
AAT-opt expression, or as the result of a nonfunctioning vector.
To address this concern, we harvested the liver from AAV8-
treated mice and measured the copy number of AAT transcripts
from the endogenous AAT-piZZ mutant allele and the delivered
AAT-opt allele. As we observed with a two-vector approach
described above, the AAT transcript copy number was re-
markably decreased in mice with an AAV8/shRNA-AAT-opt
injection compared with control mice (P < 0.05) (Fig. 4B). Im-
portantly, a much higher copy number of AAT-opt transcript was
observed in AAV8/shRNA-AAT-opt treated mice than mice
receiving scAAV8/shRNA plus AAV9/AAT-opt (323.5 vs. 21.2,
respectively) (Figs. 4C and 3C, respectively). These data indicate
that delivery of shRNA and AAT-opt into the liver using a single
AAV8 vector can efficiently knock down the piZZ transcript in
the liver and restore normal AAT levels in the blood.
Discussion
In this study, we have demonstrated that a single siRNA2 was
effective at inhibiting AAT expression. Utilization of AAV vector
to deliver this shRNA2 also efficiently silenced AAT expression
in vitro and in vivo. Over 95% knockdown of mutant AAT ex-
pression in the blood was achieved by delivery of AAV8/shRNA2
into the liver of piZZmice, an effect similar to the degree of piZZ
mRNA knockdown. Importantly, liver pathology was remarkably
improved. After liver delivery of AAV8/shRNA2 to knockdown
piZZ, intramuscular injection of AAV6/AAT vector was able to
Fig. 3. Simultaneous knock down of piZZ and restoration of wild-type AAT
in the blood, using two vectors in the liver of piZZ mice. The piZZ mice were
receiving 6 × 1010 particles of dsAAV8/shRNA followed by administration of
2 × 1011 particles of AAV9/AAT-opt vectors via tail-vein injection on the next
day. Two weeks later, the blood and the liver were collected for AAT ex-
pression (A), detection of the piZZ transcript (B), and the optimized AAT
transcript (C). The results are the mean value from four mice and error bars
indicate SD. shRNA: piZZ mice received only AAV8/shRNA2 vector via in-
travenous injection; shRNA+AAT-opt: piZZ mice with the treatment of AAV8/
shRNA2 and AAV9/AAT-opt via intravenous injection; AAT-opt: C57BL mice
were treated with only AAV9/AAT-opt via intravenous injection. *P < 0.05
compared with pre-shRNA-treated mice and control piZZ mice without
treatment.
Fig. 2. The restoration of AAT expression from AAV intramuscular injection
in PiZZ mice treated with shRNA. PiZZ mice were administered with 6 × 1010
particles of dsAAV8 vector via tail-veil injection and 1 × 1011 particles of
AAV6/AAT via muscular injection, simultaneously. At week 2 after AAV ad-
ministration, the blood was harvested and AAT expression was detected by
ELISA. The results are the mean from four mice and error bars indicate the
SD. AAV8/shRNA iv: piZZ mice with only treatment of AAV8/shRNA; shRNA
+AAT: piZZ mice with the treatment of AAV8/shRNA via intravenous and
AAV6/AAT via intramuscular injection; AAV6/AAT im: C57BL mice with in-
tramuscular injection of AAV6/AAT vector. *P < 0.05 compared with pre-
shRNA-treated mice.











rescue functional AAT levels in the blood. The optimized AAT
vector induced a higher AAT expression than wild-type AAT.
This optimized AAT transcript also escaped the degradation of
siRNA-AAT. Systemic coadministration of AAV8/shRNA2 and
AAV9/AAT-opt maintained the AAT level in the blood yet si-
lenced over 95% of piZZ AAT mRNA. Finally, injection of
a single AAV8 vector encoding both shRNA and AAT-opt also
induced AAT expression in the blood and piZZ AAT transcript
suppression in the liver of piZZ mice.
AAV has been shown to be a very promising gene-therapy
vehicle for many diseases, especially for genetic diseases, such as
hemophilia and AAT deficiency. An exciting result came from
a recent clinical trial in patients with Leber’s congenital amau-
rosis. After subretinal delivery of AAV2 encoding RP65, the
patients regained vision (10). AAV has also been used in two
clinical trials in patients with AAT deficiency via muscular de-
livery (3, 4). These and other clinical trials have demonstrated
AAV’s safety. In recent years, great progress has been made for
AAV as a gene-therapy vector, including more AAV serotypes
and variants isolated as gene-delivery vehicles and generation of
scAAV vector to enhance AAV transduction (6, 7).
Some patients with AAT deficiency, specifically the piZZ
phenotype, have liver disease resulting from accumulation of
misfolded mutant AAT protein in the liver cells. Although much
effort has been spent on increasing AAT levels by gene therapy,
including utilization of naked DNA and viral vectors to target
the liver or other tissue, these approaches only increase AAT
level in the blood to protect lung damage but do not prevent liver
disease development and progression. For prevention of liver
diseases caused by piZZ protein accumulation, several drugs
have been explored to inhibit protein polymerization and de-
crease liver injury, as well as increase the mutant protein se-
cretion. However, these agents only have transient effects. Gene
therapy may represent a very promising approach to treat the
liver diseases via decrease in synthesis or correction of the mu-
tant protein. After administration of scAAV8/shRNA2 in piZZ
mice, an efficient knockdown (>95%) of AAT expression was
observed in this study. These results indicate that nearly all
hepatocytes are transduced by scAAV8/shRNA2 vector. The
silencing efficacy of the piZZ transcript presented here using the
scAAV8 vector and a single shRNA is greater than that found
using SV40 vector-delivery of a ribozyme (50% reduction of
AAT expression), and an improvement over the knockdown ef-
fect observed in a previous study in which single-stranded AAV8
was used to deliver three shRNAs (11, 12). This result may be
caused by the improvement of scAAV over traditional ssAAV
and lower dosage of particles used in the previous AAV study.
Because the shRNAs used for this study target regions shared by
both wild-type AAT and piZZ AAT transcripts, the shRNA2 will
function for all piZZ genotypes.
In this study we also provided three approaches to restore the
concentration of AAT in the blood to protect lung damage. The
first approach is to use the muscle-tropic AAV vector (AAV6) to
deliver AAT into muscular tissues. Although the AAT level was
rescued, this approach still has disadvantages. For example,
systemic administration of AAV8/shRNA may also transduce
muscles to degrade the AAT transcript after AAV6/AAT in-
tramuscular injection. In addition, AAV transduction efficiency
is usually lower in muscles than in the liver. Utilization of an
optimized AAT construct for intramuscular injection can par-
tially address the first concern. The second approach was to
systemically apply a scAAV8/shRNA vector followed by an
AAV9/AAT-opt vector. Again, there may be some valid con-
cerns on this application, as we don’t currently know the distinct
mechanisms of AAV transduction between different serotypes:
for example, there is a possibility of shared trafficking among
serotypes even though lower neutralizing antibody cross-re-
activity has been demonstrated among AAV8 and AAV9 (7),
which may result in transduction competition between virions
within the same cell. Thus, a third strategy would be to package
both shRNA and AAT-opt cassettes into a single AAV8 virion.
Because of the size limitation of AAV payload, we could not
encapsidize the dual gene cassette into a self-complementary
format, which would improve transduction efficiency and require
a lower dose of vector to achieve the similar silence effect as
scAAV virus. It is possible that two promoters in one construct
may destabilize transgene expression from shRNA or AAT-opt,
although the piZZ AAT transcript was knocked down and si-
multaneously AAT-opt was detected after injection of AAV8/
shRNA-AAT/opt vector in our experiment (Fig. 4), supporting
the activity of both promoters of one vector backbone.
Although no acute side effects related with AAV administra-
tion in clinical trials were reported, one concern was raised about
the potential risk of capsid-specific cytotoxic T-lymphocyte
(CTL)-mediated elimination of AAV transduced target cells
(13). Although a capsid-specific CTL response can be elicited via
both classic class I antigen presentation and cross-presentation
pathways, the concept of capsid-specific CTL-mediated elimi-
nation of AAV-transduced target cells has not been reproduced
in mouse models (14). One interpretation for the discrepancy
between human and mouse is that transgene tolerance has been
demonstrated by AAV vector targeting the liver in mice. Recent
studies have shown that the liver tolerance can be reversed by
up-regulation of inflammatory signals (15). Accumulation of
Fig. 4. Blood AAT restoration from the liver transduced with a single vector
to deliver shRNA and optimized AAT. The piZZ mice were administrated with
3 × 1011 particles of AAV8/shRNA-AAT/opt vectors (which encode shRNA and
optimized AAT cDNA) via tail-vein injection. Two weeks later, AAT expres-
sion in the blood (A) and the transcript of piZZ (B) and optimized AAT (C)
were detected in the blood and the liver, respectively. All datapoints are the
mean of four mice and error bars indicate SD. shRNA-GFP: piZZ mice with the
treatment of AAV8/shRNA2-GFP vector via intravenous injection; shRNA-
AAT-opt: piZZ mice received AAV8/shRNA-AAT-opt vector by intravenous
injection. AAT-opt: C57BL mice were treated with AAV8/shRNA-AAT-opt via
intravenous injection. *P < 0.05 compared with pre-shRNA-treated mice and
control piZZ mice without any treatments.
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piZZ misfolded protein in the endoplasmic reticulum can spe-
cifically activate autophagy (16), and autophagy activation is
associated with an inflammatory response (17). Future studies
should address whether capsid-specific CTLs are able to elimi-
nate AAV-transduced hepatocytes and lead to therapeutic fail-
ure in mice with the piZZ mutation.
Overexpression of shRNA delivered by gene-therapy vectors
can induce cytotoxicity, resulting in organ failure and fatality in
animal models because of oversaturation of endogenous cellular
RNAi factors (18). No mice in the present studies died of the
shRNA treatment, perhaps because of the low dose of shRNA
vector and the weak H1 promoter used. In summary, our results
demonstrated that an AAV vector can be used to deliver AAT
shRNA to the liver and efficiently knock down the AAT tran-
script to prevent liver diseases. Utilization of intramuscular in-
jection of AAV6/AAT and coadministration of AAV9/AAT-opt
with AAV8/shRNA, as well as delivery of a single AAV8 vector
encoding both shRNA and AAT-opt, could restore AAT ex-
pression in the blood to prevent liver disease development and
treat low-AAT related lung diseases. The approach presented
here has potential application to other diseases associated with
misfolded proteins, such as Huntington disease and amyotrophic
lateral sclerosis.
Materials and Methods
Generation of AAV Constructs. At first, the self-complementary shRNA AAV
vector (pSC-H1–shRNA-empty) was constructed by swapping of fragment
from pSUPER.retro.puro (OligoEngine) into pSC-TTRmvmFIX digested with
endonucleases EcoRI and BsrGI (9), in which shRNA was driven by the RNA
Poly III H1 promoter. The annealing of pairing oligos (Table S1) generated
a BamHI terminus on the 5′ end and a Hind III terminus on 3′ end, which was
cloned into the dsAAV/siRNA-empty backbone digested with BglII (the cor-
rect clone loses BglII site) and HindIII to form constructs pSC-shRNA1, pSC-
shRNA2, and pSC-shRNA3. Codon optimization of human AAT cDNA specific
for mouse tissues was designed and synthesized by Geneart. After digestion
with EcoRI and NotI, the AAT-opt fragment was used to substitute the AAT
fragment of pTR/CBA-AAT, generating the clone pTR/CBA-AAT-opt. To clone
the pTR-shRNA-AAT/opt construct, the fragment from pSC-shRNA-AAT2
by the digestion of EcoRI (blunt) and BsrGI was inserted into pTR/CBA-AAT
cut by BglII (blunt) and BsrGI. The clone pTR-shRNA-GFP was obtained by
swapping the AAT-opt fragment in pTR-shRNA-AAT-opt with digestion
of EcoRI (blunt) and NotI by the GFP fragment in pTR-eGFP with digestion of
AgeI (blunt) and NotI. pTR-CBA-AAT-piZZ was generated by introduction
of the piZZ mutation into the pTR/CBA-AAT plasmid.
Animal Experiments. C57BLmice and BALB/c were purchased from the Jackson
Laboratory. The piZZ transgenic mice have been described before (12)
(generously provided by Terence R. Flotte, University of Massachusetts
Medical School, Worcester, MA). All mice were maintained in a specific
pathogen-free facility at the University of North Carolina at Chapel Hill. All
procedures were approved by the University of North Carolina Institutional
Animal Care and Use Committee.
ELISA for Detection of AAT.A 96-well plate was coated with rabbit anti-human
AAT antibody (Sigma) at 10 μg/mL overnight at 4 °C. After blocking with the
sample dilution solution (PBS with 2.5% bovine albumin and 0.05% Tween-
20) for 1 h at room temperature, diluted serum in 100 μL total was added to
the well and incubated at room temperature for 2 h. After washing four
times with PBS, 100 μL of HRP-conjugated goat anti-human AAT antibody
(Abcam) (10 μg/mL) was added for 1 h at room temperature. After further
washing, the color was developed by addition of the TMB substrate (Pierce)
and arrested by 10% H2SO4. Optical density was read with an ELISA plate
reader. Murine AAT was nondetectable with this assay.
Statistical Analysis. Statistics were performed using the Student t test. A P
value of less than 0.05 was considered a significant difference and is marked
in the figures with an asterisk.
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